Scopolamine Prevents Mitochondrial Dysfunction in Depressive Disorder, Potentially via Its Anti-Inflammatory Effects Authors: Yunxiao Zhang, Hao Fu, Wanpu Yan, Shuo Li, Jiheng Chen Published: 2026 ABSTRACT AbstractBackgroundDepression imposes a heavy global disease burden accompanied by mitochondrial injury and neuroinflammation predominantly in the prefrontal cortex. Using a chronic unpredictable mild stress (CUMS) rat model, this study aimed to explore the impacts of scopolamine on brain mitochondrial function and its underlying mechanisms.MethodsTwelve male Wistar rats aged 6–8 weeks were randomly assigned to three groups: control, CUMS, and CUMS+scopolamine. Rats received 4 weeks of corresponding treatments, followed by behavioral tests to assess depression-like phenotypes. Transmission electron microscopy (TEM) was used to observe neuronal and mitochondrial morphological alterations in the prefrontal cortex. Quantitative PCR was performed on whole-brain homogenates to detect expression of PGC-1α, Drp1, MFF, mfn2 and GPX4. Western blot and ELISA were further adopted to probe associated inflammatory signaling pathways.ResultsScopolamine alleviated CUMS-induced mitochondrial ultrastructural damage in the prefrontal cortex. PCR results demonstrated that scopolamine reversed stress-triggered upregulation of PGC-1α, Drp1 and MFF as well as downregulation of mfn2, while elevating the level of anti-ferroptotic GPX4. Additionally, Western blot and ELISA data indicated that scopolamine was associated with suppressed NF-κB activation and reduced concentration of pro-inflammatory IL-6.ConclusionScopolamine safeguards brain mitochondrial structure and homeostasis in depressive rats, manifested as normalized expression of PGC-1α, Drp1, MFF, mfn2 and GPX4. Such protective effects may be correlated with scopolamine’s anti-inflammatory capacity (downregulation of IL-6) via NF-κB pathway suppression. This study bears several important limitations that constrain the robustness of our mechanistic conclusions. Future investigations with larger sample sizes, as well as animal models employing NF‑κB‑specific inhibitor intervention or NF‑κB gene knockout, are therefore warranted.Keywords: depression, scopolamine, mitochondrial function, anti-inflammatory, NF-κB pathway Background According to the World Health Organization, depression will account for the largest burden of disease worldwide by 2030.1 The disease burden of depression is characterized by continuous and long-term depression, repeated remission and deterioration, and in some instances, suicidal tendencies.2,3 Depression not only causes serious mental anguish but also affects basic biological processes such as blood coagulation, metabolism, autonomic nerve function, and neuroendocrine activity.4–6 However, the etiology of depression remains unclear at present. Some studies have shown that the pathophysiology of major depressive disorder is coordinated by several synergistic mechanisms, including monoamine and neuroendocrine components, neurotrophic factors, epigenetic mechanisms, oxidative stress, inflammation, and mitochondrial dysfunction.7–9 Mitochondria are organelles that are directly and indirectly responsible for a variety of cellular functions and signaling cascades and are considered the central platform by which various cellular events are conducted.10,11 Studies have suggested that alterations in mitochondrial dynamics and mitophagy may underlie the pathogenesis of some neurodegenerative and psychiatric diseases.12–14 Electron microscopy performed on tissue and blood from patients with bipolar disorder or schizophrenia revealed abnormal mitochondrial structure, number, size, and distribution15–17 and identified an imbalance between protein genes and proteins involved in mitochondrial dynamics.18,19 Studies have also revealed that mitochondrial dysfunction and dysregulation of neuroinflammatory pathways play a role in the pathophysiology of major depressive disorder. For instance, compared with those from healthy control subjects, the mitochondrial dynamics in peripheral blood mononuclear cells from patients with major depressive disorder exhibited an increase in mitochondrial fragmentation, which is aggravated in the inflammatory state.20 The results of these studies suggest that preventing damage to mitochondrial function during depression may serve as an effective treatment approach for depression. Currently, most traditional antidepressants drugs required continuous administration for 2–4 weeks to achieve clinical efficacy, and accompanied by obvious side effects such as gastrointestinal discomfort, weight gain and sexual dysfunction, which greatly limits clinical application. It is urgent to develop rapid-onset antidepressants and clarify their underlying molecular mechanisms. Scopolamine blocks muscarinic cholinergic receptor. Recent studies have shown that scopolamine has a significant antidepressant effect.21,22 In one study, scopolamine was associated with lower depression scores among patients with depression, compared with placebo and appears to be dose dependent.23 Furthermore, among patients treated with scopolamine in this previous study, the improvement in clinical symptoms persisted for >2 weeks, far exceeding the expected duration of scopolamine’s direct effect on muscarinic receptors, which indicated that its mechanism of action exceeded its direct muscarinic cholinergic antagonism effects.23 Actually, scopolamine may also protect lysosomal and mitochondrial functions. Studies have shown that scopolamine can stabilize cell membranes and lysosomal membranes to reduce capillary permeability, reduce inflammatory cytokine secretion, and improve the function of the microcirculation in rats with septic shock.24 The effects of scopolamine on stress control and improvement in the microcirculation may contribute to its protective effects on lysosomal membranes and mitochondria.24 However, currently few studies have investigated the effects of scopolamine on mitochondrial function in depression. Therefore, in the present study, we sought to determine the effects of scopolamine on mitochondrial function during depression and to identify relevant mechanisms of action of this drug. Methods Animals Sixteen 6- to 8-week-old male Wistar rats (weight, 180–220 g) were purchased from Vital River Laboratory Animal Technology (Beijing, China). All rats were specific pathogen-free (SPF) grade, healthy and immune-normal, wild-type without genetic modification, and had no previous experimental or surgical procedures. Animals were reared at 22°C with 2 rats per cage and a 12-h light, dark cycle, with provision of ordinary rat food and tap water. Rats were adaptively fed for 1 week and then underwent the sucrose preference test (SPT). Rats with sucrose preference scores < 70% were excluded from subsequent modeling experiments (n = 4 excluded), leaving 12 eligible rats for random grouping. The experimental procedures were approved by the Experimental Animal Ethics Committee of Peking University Cancer Hospital (approval ID: EAEC 2023‑01). The experimental procedures were approved by the Experimental Animal Ethics Committee of Peking University Cancer Hospital (EAEC 2023–01) and performed in accordance with the Regulations on Administration of Laboratory Animals of the People’s Republic of China and ARRIVE 2.0 guidelines for laboratory animal welfare, as well as the latest American Veterinary Medical Association (AVMA) guidelines for animal anesthesia and euthanasia. During the experiments, cage positions were replaced regularly to eliminate environmental interference and all possible measures were taken to minimize pain and discomfort for the animals. Animal Grouping and Modeling Rats (n = 12) were randomly divided into 3 groups using a random number table method: normal control (Ctrl) group, chronic unpredictable mild stress (CUMS) group, and chronic unpredictable mild stress plus scopolamine (CUMS+Scop) group. The CUMS model was developed in accordance with Katz’s method, with minor improvements. A total of 9 stimuli were randomly administered for 4 weeks, including 24-h light and 24-h dark inversion, swimming in ice water (4°C), withholding of water for 24 h, withholding of food for 24 h, tail clamping for 1 min, shocking of foot soles with 30 V for 5 s, horizontal vibration for 5 min (160 hz), and exposure to a 40°C environment for 5 min. Rats were exposed to 1 stimulus per day, each stimulus was administered at least 3 separate times, and the same stimuli could not be used continuously so that the animals could not predict the occurrence of a stimulus. The Ctrl group did not receive any stimulation. From the eighth day of modeling (ie, excluding the week of adaptive feeding), rats in the CUMS+Scop group were administered an intraperitoneal injection of scopolamine at 25 ug/kg for 3 days followed by withdrawal for 4 days, and this was repeated 3 times (for a total of 21 days). Rats in the Ctrl and CUMS groups were administered normal saline at an equivalent dose at the same time points. Behavioral Testing After 4 weeks of CUMS exposure or no exposure (Ctrl group), all rats underwent the open field test (OFT), tail suspension test (TST), and sucrose preference test (SPT) sequentially in a randomly arranged order by researchers blinded to experimental grouping. All behavioral tests were conducted in a room with sound attenuation, and behavioral tests were performed once a day to avoid errors caused by physiological and psychological effects on rats. OFT Rats were gently placed in the corner of a 100 cm × 100 cm × 35 cm pleated plastic box and allowed to move freely in dim light for 5 min. For the first 2 min, rats were allowed to adapt to the field. For the next 3 min, a camera was used to record the movement of the rat, and the total distance that each rat moved was calculated by an observer who was blinded to the experimental conditions. Smart 3.0 software (Panlab, Harvard Apparatus, Holliston, MA) was used to analyze videos. TST Rats were suspended by fixing three-fourths of their tail on the hook of a suspension box so that the rat was in an upside-down position. The head of the rat was kept a fixed distance from the bottom of the suspension box, and a camera was placed in horizontal alignment with the suspension device. The time that the rat was immobile during the period of assessment was recorded. Rats were kept in the suspension position for 6 min, and the duration that the rat was immobile during the last 4 min of this period was recorded. SPT Before the experiment, rats were trained to adapt to sucrose water in a quiet room. Two water bottles were placed in each cage at the same time. For the first 24 h, both bottles were filled with 1% sucrose water. For the following 24 h, 1 bottle contained 1% sucrose water, and the other bottle contained pure water. Then, after 24 h of fasting and water deprivation, the SPT was performed. Each rat was given access to 2 bottles of quantified water: 1 bottle of 1% sucrose water and 1 bottle of pure water. After 24 h, the 2 bottles were weighed to calculate total water consumption, sucrose water consumption, pure water consumption, and sucrose water preference (sucrose water consumption/total water consumption × 100%). Sampling and Sample Processing All animal anesthesia and euthanasia procedures in this study were strictly performed in strict accordance with the latest AVMA guidelines for the humane euthanasia of laboratory animals, adhering to standardized veterinary operating specifications to minimize animal pain, distress and suffering. For tissue collection, rats were subjected to deep anesthesia via intraperitoneal injection of 10% chloral hydrate solution (40 mg/kg body weight, analytical grade), a commonly used and safe anesthetic agent for rodent experiments. The chest was then opened, the ascending aorta was cannulated, and the right atrium was cut open. Next, 250 mL of 0.1 mol/L phosphate-buffered saline (PBS) was perfused into the rat, followed by 150 mL of fixation solution (4% paraformaldehyde plus 0.1 M PBS plus 0.5% glutaraldehyde mixture) for 30 min. Limited by tissue perfusion and ultrathin section preparation workload, only prefrontal sensory area tissue of 1 single rat in each group was excised by use of a sharp blade and fixed in 2.5% glutaraldehyde (0.1 mmol/L PBS [pH 7.4]) for electron microscopic ultrastructural observation, which is a major limitation of current study. All remaining experimental rats were humanely euthanized by rapid decapitation under continuous deep anesthesia to eliminate unnecessary suffering, and the whole brain was harvested and frozen in liquid nitrogen for Western blot analysis, quantitative polymerase chain reaction (PCR), and enzyme-linked immunosorbent assay (ELISA). Electron Microscopic Observation of the Prefrontal Sensory Area in Rats Prefrontal sensory area tissue was fixed with glutaraldehyde (as mentioned just above) and fixed again in 1% osmium tetroxide. Tissue was then cleaned, dehydrated, embedded, and solidified. Ultrathin tissue sections (thickness, ~ 50 nm) were harvested from the prepared embedded blocks by use of an ultramicrotome and were then double-stained. An H-7650 transmission electron microscope was used to analyze the structural changes in neurons, mitochondria, and synapses in the bilateral prefrontal sensory areas in rat brain specimens. RNA Isolation and Real-Time Quantitative PCR Detection Total RNA was extracted from rat brain tissue using TRlzol reagent (Invitrogen), and first-strand cDNA was synthesized by use of a universal reverse transcription kit (Yeasen Biotechnology, 11141ES60, Shanghai, China). The cDNA was subjected to PCR analysis. Qualitative PCR was performed using the Realtime PCR Fluorescence Quantification Kit (Yeasen Biotechnology, 11201es08, Shanghai, China). The primer sequences used are shown in Table 1. Expression levels were normalized to GAPDH, and 2–ΔΔCt was used to represent the relative expression level of the gene. Table 1Primers Used in the Study ExperimentsProtein MeasuredForward (F) or Reverse (R)Primer SequenceAmplified Fragment Size, Base PairsGAPDHFGGCAAGTTCAACGGCACAG142RCGCCAGTAGACTCCACGACAPGC1αFTGGCACGCAGTCCTATTCATTGTT255RCGGTGTCTGTAGTGGCTTGATTCATDrp1FCAGGAACCGACAACAGGCAACT154RCAACTGGAACTGGCACATCTAGCAMFFFGCCAGAATGGACAGTTGGTCAGAA115RCGTCTCAATGAAGCCGCATCTACCmfn2FACGGATTAAGCAGATGACAGAGGAAG280RCCGCACAGACACAGGAAGAAGGGPX4FGCAGGAGCCAGGAAGTAATCAAGAA267RTAGCACGGCAGGTCCTTCTCTATC Primers Used in the Study Experiments Western Blotting Brain tissue was frozen in a liquid nitrogen tank and transferred to a −80 °C refrigerator for storage. Tissue was then lysed in precooled Ripa buffer containing protease inhibitor mixture, ground thoroughly, and centrifuged; the supernatant was then analyzed using the Bradford protein concentration assay to determine the protein concentration. After denaturation of sample protein, 50 ug of sample protein was separated by use of 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (Sinopharm, 30166428, Shanghai, China) and then transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, IPVH00010, Bradford, MA, USA). The PVDF membrane was blocked by the use of TBST (blocking solution) containing 5% milk for 2 h at room temperature on a shaker. The corresponding primary antibody was diluted by use of TBST containing 2% bovine serum albumin, and the PVDF membrane was soaked in the primary antibody incubation solution and incubated overnight at 4 °C. Horseradish peroxidase–labeled secondary antibody was diluted with blocking solution (1:5000 dilution), and the PVDF membrane was immersed in secondary antibody incubation solution and then incubated at room temperature for 1 h on a shaker. PVDF membranes were treated with enhanced chemiluminescence reagent (Beyotime, P0018S-2, Shanghai, China) and exposed using a fully automated chemiluminescence image analysis system (Tanon, 5200, Shanghai, China). Gray values from the exposures were analyzed using image J software. ELISA Frozen brain tissue was lysed by use of radio-immune precipitation assay buffer and then homogenized on ice. The supernatant was collected after centrifugation and stored at freezing temperature for further analysis. An ELISA kit (Ruixin, RX302856R, Quanzhou, China) was used to quantify the expression of cytokines, in accordance with the manufacturer’s protocol. Statistical Analysis Data are presented as mean ± standard deviation. Statistical analyses were performed using SPSS software (version 22.0, IBM Corporation, Armonk, NY) by an investigator who was blinded to the treatment conditions. Before parametric statistical test, Shapiro–Wilk test was applied to verify data normality; Levene’s test was used to detect homogeneity of variance, complying with ARRIVE 2.0 reporting standards. All datasets passed normality and homogeneity test (p > 0.05), thus one-way ANOVA followed by Bonferroni post hoc multiple comparison was adopted for inter-group comparison. Statistical significance was defined as p < 0.05. Post-hoc statistical power analysis was performed using G*Power 3.1 software for one-way between-group analysis of variance (ANOVA). Given the lack of previously published data reporting effect sizes for mitochondrial and inflammatory biomarkers in CUMS rat models, we adopted widely recognized Cohen’s standard thresholds for effect size classification as the statistical reference. Two scenarios were evaluated: a large effect size (Cohen’s f = 0.4) and a moderate effect size (Cohen’s f = 0.25), with fixed parameters of three experimental groups (k = 3) and significance level α = 0.05. Under the large-effect assumption (f = 0.4), post-hoc calculation based on our present sample size (n = 4 per group) yielded an actual statistical power of only 0.612, below the conventional benchmark of 0.8. A priori power calculation under identical parameters indicated that a minimum of 7 animals per group is required to reach the target power of 0.8. Under the more conservative moderate-effect assumption (f = 0.25), the statistical power of n = 4 per group decreased to merely 0.215, while at least 14 rats per group would be necessary to achieve sufficient statistical power. This dual power assessment demonstrates that the current sample cohort carries a high risk of Type II error, especially for mild-to-moderate biological differences between groups. This statistical limitation is comprehensively elaborated in the independent Study Limitations subsection, and we plan to enlarge animal sample sizes to n ≥ 7 per group in subsequent validation trials to improve statistical robustness. Results Behavioral Experiment Results To validate the CUMS depression model, we used behavioral assays, including the OFT, TST, and SPT, to evaluate depression-like behaviors, such as despair and anhedonia. Our results showed that, after 28 days of modeling, the CUMS group had shorter movement distance (p < 0.01) (Figure 1A), longer immobility time (p < 0.01) (Figure 1B), and lower interest in 1% sucrose solution (p < 0.001) (Figure 1C), compared with the Ctrl group, which signified depression-like behavior. The above test results were not statistically different between the Ctrl group and the CUMS+Scop group, indicating that scopolamine may play a role in preventing the occurrence of depression-like behavior induced by CUMS in rats. Scopolamine attenuates CUMS-induced depressive symptoms in rats. (A) Total distance rats moved during the assessment period. (B) Total time rats were immobile during the assessment period. (C) Sucrose water preference during the assessment period. Data are mean ± standard deviation (n = 4). ##p < 0.01, ###p < 0.001, versus the Ctrl group. Scopolamine Can Prevent Morphologic Changes Among Neuronal Cells and Mitochondria in the Rat Brain During Depression We assessed morphologic changes among neurons and mitochondria in rat prefrontal cortex tissue by use of transmission electron microscopy, and only one representative sample from single rat per group was displayed. In the Ctrl group, neuronal cells had a regular morphologic appearance, the nucleus was large and round, euchromatin was abundant in the nucleus, and the nucleolus was obvious. Furthermore, the cristae of mitochondria in the cytoplasm were clear and the structure was complete, and the presynaptic membrane, synaptic cleft, and postsynaptic membrane were clear and complete (Figure 2A). In contrast, in the CUMS group, neuronal cells had an irregular morphologic appearance, the nucleus was diminished in size, heterochromatin was distributed around the nucleus, and the cytoplasm was diminished in size. The structures of the mitochondrial membrane and the cristae in the cytoplasm were partially blurred. The structures of the presynaptic membrane and the postsynaptic membrane were fuzzy, and the synaptic space was not clear (Figure 2B). In the CUMS+Scop group, the neuronal cell structure was relatively complete, the structures of the mitochondrial membrane and the cristae were relatively clear, and the synaptic cleft and the synaptic structure were improved (Figure 2C). Electron microscopy images of the prefrontal cortex in rats (only one representative sample from single rat per group was displayed). Arrows indicate the structure of interest in each panel. (A) The morphologic appearance of neuronal cells in the Ctrl group was regular. The cristae of mitochondria were clear, and the structure was complete. The synaptic structure was clear. (B) The morphologic appearance of neuronal cells in the CUMS group was irregular, and the nucleus was diminished in size. The structures of the mitochondrial membrane and the cristae were partially blurred. The synaptic structure was not clear. (C) The neuronal cell structure in the CUMS+Scop group was relatively complete. The structures of the mitochondrial membrane and the cristae were relatively clear. The synaptic structure was improved. The image was taken at a magnification of ×10, 000. Effects of Scopolamine on Mitochondrial Biogenesis, Mitochondrial Dynamics, and Ferroptosis in Rat Brain Tissue During Depression To further investigate the effect of scopolamine on mitochondrial biogenesis and mitochondrial dynamics during depression, we analyzed changes in levels of PGC-1α, Drp1, MFF, and mfn2 in rat brain tissue by use of PCR. PGC-1α was lower in the CUMS group than in the Ctrl group (p < 0.001). The level of PGC-1α was not statistically different between the CUMS+Scop group and the Ctrl group (p = 0.053). In addition, Drp1 and MFF were higher in the CUMS group than in the Ctrl group (p < 0.001 and p < 0.01, respectively), whereas mfn2 was lower in the CUMS group than in the Ctrl group (p < 0.01). The levels of Drp1, MFF, and mfn2 were not statistically different between the CUMS+Scop group and the Ctrl group (p = 0.308, p = 0.926 and p = 0.078, respectively) (Figure 3). Effects of scopolamine on mitochondrial biogenesis, mitochondrial dynamics, and ferroptosis during depression. Scopolamine prevents decreases in PGC-1α and mfn2 and increases in Drp1 and MFF and is associated with higher levels of GPX4 after depression stress. Data are mean ± standard deviation (n = 4). ##p < 0.01, ###p < 0.001, versus the Ctrl group. Mitochondrial function is directly involved in ferroptosis, which can lead to a variety of diseases, including neurological diseases. Therefore, we assessed levels of GPX4, which plays a critical role in preventing ferroptosis, in rat brain tissue. GPX4 was lower in the CUMS group than in the Ctrl group (p < 0.01). The level of GPX4 was not statistically different between the CUMS+Scop group and the Ctrl group (p = 0.147) (Figure 3). Scopolamine Protects Mitochondrial Function During Depression by Attenuating NF-κB Signaling To further investigate the mechanisms by which scopolamine protects mitochondrial function during depression, we explored potential pathways by use of Western blot analysis detecting phosphorylated p-NF-κB protein, as well as ELISA detecting inflammatory factor IL-6, while total NF-κB was not detected due to exhausted brain tissue resources, which is acknowledged as an experimental limitation of this work. The results showed that, chronic stress was associated with upregulated expression of p-NF-κB (p = 0.039) and concentration of inflammatory factor IL-6 (p = 0.002) in rat brain tissue, whereas scopolamine was associated with inhibited expression of p-NF-κB (p = 0.044) and lower levels of IL-6 (p = 0.004) compared with the CUMS group. (Figure 4). Scopolamine may protect mitochondrial function during depression by attenuating NF-κB signaling. The results of Western blot analysis (detecting p-NF-κB) and ELISA (detecting IL-6) show that, chronic stress is associated with upregulated expression of NF-κB (p = 0.039) and concentration of IL-6 (p = 0.002) in rat brain tissue, whereas scopolamine is associated with inhibited expression of NF-κB (p = 0.044) and lower levels of IL-6 (p = 0.004). The loading control and target shown in the image were not run on the same gel. Total NF-κB was not detected due to exhausted brain tissue resources, which is acknowledged as an experimental limitation of this work. Data are mean ± standard deviation (n = 3). 1 = Ctrl, 2 = CUMS, 3 = CUMS+Scop. ##p < 0.01, versus the Ctrl group. **p < 0.01, versus the CUMS group. Discussion The role of mitochondria in depression is an area of increasing interest,9,20 and compromised or deficient mitochondrial function is considered an important factor in the occurrence and development of depression.9,20 In the present study, we investigated the protective effects of scopolamine on mitochondrial function during depression. Our results show that scopolamine can protect the mitochondrial structure of the prefrontal cortex in rats during depression and can prevent a decrease of PGC-1α in brain tissue, which was closely related to mitochondrial biogenesis.25 Depression is associated with increased levels of Drp1, MFF, and GPX4 and decreased levels of mfn2. Our results show that, in rats, scopolamine can prevent these changes and thereby avert excessive mitochondrial fragmentation and neuronal ferroptosis induced by depression-related stress.26,27 Our results also show that the protective effect of scopolamine on mitochondria may be related to the NF-κB signaling pathway. Scopolamine was associated with inhibited upregulation of NF-κB expression and lower levels of IL-6. The prefrontal cortex plays an important role in the regulation of higher cognitive processes and stress-induced hypothalamic pituitary adrenal activity.28 As detailed in the Results section, we found that scopolamine is associated with fewer and less severe morphologic changes in neurons and mitochondria in the rat brain during depression. Consistent with our findings, other studies have found that repeated stress can cause morphologic changes in the prefrontal cortex, including reduced number and density of dendritic spines of brain neurons, reduced total length of dendrites, and effects on the presynaptic and postsynaptic membrane structure.29 In addition, depression-related stress can cause mitochondrial ultrastructural abnormalities, obscuring the structure of the mitochondrial membrane and cristae and reducing the length of mitochondria and the number of postsynaptic mitochondria.30 Studies have shown that rapid-acting antidepressants, such as ketamine and scopolamine, can quickly enhance neural plasticity and improve neuronal morphologic appearance and structure,31,32 which is consistent with the results of the present study. It should be noted that only prefrontal cortex tissue was detected in current research, and multi-brain-region, such as hippocampus, amygdala or other depression-related brain regions will be detected in subsequent research to clarify regional specificity. We also investigated the effect of scopolamine on mitochondrial function during depression. For mitochondrial biogenesis marker PGC-1α: CUMS stress significantly suppressed PGC-1α transcription, which impairs new mitochondria synthesis and aggravates energy metabolism disorder in neurons,33 while intermittent scopolamine treatment reversed this inhibitory effect, indicating scopolamine can restore mitochondrial biogenesis capacity under stress state. For mitochondrial dynamic balance genes: Drp1 and MFF are key promoters of mitochondrial outer membrane fission, their overexpression under chronic stress leads to massive fragmented dysfunctional mitochondria,26 while mfn2 mediates mitochondrial fusion to maintain tubular intact mitochondria structure, its downregulation breaks fusion-fission homeostasis.26 Scopolamine normalized the expression of above three fission/fusion genes, stabilizing mitochondrial morphology. Consistent with our results, previous studies have also found that, compared with nondepressed mice, depressed mice had suppressed mitochondrial biogenesis signaling (decreased PGC-1α), lower mfn1 (marker of mitochondrial fusion), and higher Drp1 (marker of mitochondrial fission).30 Ferroptosis can lead to a variety of diseases, including neurological diseases.34 Mitochondrial dysfunction plays an important role in ferroptosis.35 Therefore, we investigated the levels of GPX4 in rat brain tissue whose degradation can be induced by stress triggers lipid peroxidation and neuronal ferroptosis.36 Our results—lower GPX4 in the CUMS group than in the Ctrl group and no difference between the CUMS+Scop group and the Ctrl group—suggest that scopolamine inhibits ferroptosis in the rat brain during depression. We also attempted to identify mechanisms by which scopolamine improves mitochondrial dysfunction during depression. Previous studies have suggested that the antidepressant effect of scopolamine may be related to its m-TOR receptor regulatory mechanism.22 However, this mechanism does not fully explain the protective effect of scopolamine on mitochondria during depression. Studies have also suggested that inflammation may be involved in mitochondrial dysfunction during depression. Patients with major depressive disorder with high levels of C-reactive protein were found to have more-severe changes in mitochondrial dynamics and functional damage than similar patients with low levels of C-reactive protein.20 Preclinical and clinical studies have reported a relationship between depression and neuroinflammation.37,38 Peripheral administration of lipopolysaccharide induces overactivation of microglia and activation of the NF-κB signaling pathway, which results in the production of proinflammatory cytokines associated with depressive-like behavior.39 In the present study, we found that phosphorylated NF-κB was higher in the CUMS group than in the Ctrl group, whereas phosphorylated NF-κB was lower in the CUMS+Scop group than in the CUMS group. Downstream inflammatory cytokine IL-6 was higher in the CUMS group than in the Ctrl group and recovered to control level after scopolamine intervention. But due to exhausted brain tissue resources, the total NF-κB was not detected in the present study, which is acknowledged as an experimental limitation of this work. Combined with mitochondrial phenotype and molecular detection data, we potentially infer that NF-κB inflammatory pathway suppression may be correlated with scopolamine-mediated mitochondrial protection, but we cannot confirm direct causal regulatory relationship only based on current correlative data, and specific NF-κB inhibitor intervention or NF-κB gene knockout animal models are required in future research to verify the direct causality between NF-κB inhibition and mitochondrial improvement. We administered scopolamine intraperitoneally at a dosage of 25 ug/kg (CUMS+Scop group) over a 3-day course followed by 4 days of discontinuation and repeated this 3 times. Previous studies have found that subchronic administration of scopolamine is necessary to alleviate depressive symptoms and induce rapid antidepressant effects. Continuous administration of scopolamine for 4 days can significantly reverse unpredictable chronic mild stress–induced behavior, whereas administration of scopolamine as a single dose (at the same level) does not alleviate the depression-like symptoms mentioned earlier.40 This need for continuous administration of scopolamine is consistent with previous clinical data on scopolamine in the treatment of patients with major depressive disorder and bipolar disorder.21,23 From clinical transformation perspective, intermittent medication regimen can reduce total drug exposure dose, lower muscarinic cholinergic side effects such as dry mouth, blurred vision and tachycardia, greatly improving clinical safety and patient compliance, which provides valuable reference for subsequent clinical dosage exploration of scopolamine as rapid antidepressant. The present study has several obvious limitations that should be fully acknowledged to avoid overinterpreting the research conclusions.1 Small animal sample size (n = 4 per group for behavioral and molecular tests): Post-hoc power calculation proved that current sample only has sufficient statistical power to detect large inter-group effect size, with high risk of Type II error, which may ignore mild-to-moderate protective effects of scopolamine on partial molecular indicators. Future experiments will expand sample quantity to n ≥ 7 per group to improve statistical reliability.2 Electron microscopic ultrastructural observation limitation: Only one rat tissue sample per group was collected for transmission electron microscopy, without multi-animal biological repetition and quantitative statistical analysis of mitochondrial morphological indicators (mitochondrial cross-sectional area, cristae density, synaptic cleft width), thus the ultrastructural conclusion lacks quantitative data support. Subsequent research will collect prefrontal tissue from at least three rats in each group for quantitative mitochondrial morphology statistics.3 Only phosphorylated NF-κB (p-NF-κB) rather than total NF-κB protein was tested to evaluate NF-κB signaling activation, which restricts accurate calculation of NF-κB phosphorylation levels, weakening the reliability of pathway-related conclusions. Future repeated experiments will simultaneously detect total NF-κB and p-NF-κB and preserve molecular weight marker records for full image standardization.4 Correlative rather than causal evidence between NF-κB pathway and mitochondrial protection: The current study only observed synchronous alteration of NF-κB phosphorylation and mitochondrial function markers after scopolamine intervention, without specific pathway gain/loss-of-function verification experiments, unable to confirm that NF-κB inhibition directly mediates scopolamine’s mitochondrial protective activity.5 Single brain region detection: Only prefrontal cortex tissue was analyzed, whether scopolamine has consistent mitochondrial and anti-inflammatory regulatory effects on other depression-associated brain regions remains unknown.6 Limitation of rodent CUMS model translation: The chronic unpredictable mild stress rodent model cannot fully simulate the complex multi-factor pathogenesis of clinical major depressive disorder including genetic susceptibility, life trauma and long-term social pressure, species differences between rat and human brain cell composition, inflammatory response characteristics limit direct clinical extrapolation of our experimental results. Conclusion Scopolamine protects mitochondrial ultrastructure and mitochondrial homeostasis function in the brain of CUMS-induced depression model rats. These beneficial mitochondrial protective effects are correlated with scopolamine’s anti-inflammatory properties through negative regulation of the NF-κB signaling pathway. Current research is limited by small animal sample size, single-animal electron microscopy observation and lack of total NF-κB detection and pathway intervention verification experiments, so the robustness of mechanistic conclusions were restricted, and we cannot confirm direct causal regulatory relationship only based on current correlative data. Larger sample size and specific NF-κB inhibitor intervention or NF-κB gene knockout animal models, as well as large animal preclinical experiments and preliminary clinical observation are required in future research to verify the direct causality between NF-κB inhibition and mitochondrial improvement, and to further promote translational application of scopolamine as rapid antidepressant. Acknowledgments We would like to thank Ke-neng Chen for his helpful comments during articlepreparation. Funding Statement No funding was received for conducting this study. Abbreviations Ctrl, control; CUMS, chronic unpredictable mild stress; CUMS+Scop, chronic unpredictable mild stress plus scopolamine; ELISA, enzyme-linked immunosorbent assay; OFT, open field test; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PVDF, polyvinylidene difluoride membrane; SPT, sucrose preference test; TST, tail suspension test. Data Sharing Statement The raw and processed datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. All data fully support the findings reported in this article, with no ethical, privacy, or security restrictions limiting data sharing. Ethics Approval and Consent to Participate The experimental procedures were approved by the Experimental Animal Ethics Committee of Peking University Cancer Hospital (EAEC 2023-01) and performed in accordance with the Regulations on Administration of Laboratory Animals of the People’s Republic of China and ARRIVE 2.0 guidelines for laboratory animal welfare, as well as the latest American Veterinary Medical Association (AVMA) guidelines for animal anesthesia and euthanasia. Author Contributions Yunxiao Zhang and Hao Fu are first co-authors. Yunxiao Zhang: Conceptualization, Methodology, Formal analysis, Investigation, Writing – Original Draft, Visualization. Hao Fu: Conceptualization, Methodology, Investigation, Data curation, Visualization, Writing – Original Draft. Wanpu Yan: Methodology, Validation, Data curation, Writing – review & editing. Shuo Li: Investigation, Resources, Data curation, Writing – Review & Editing. Jiheng Chen: Conceptualization, Supervision, Project administration, Validation, Writing – Review & Editing. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure All authors declare no conflicts of interest related to this study. References Associated Data Data Availability Statement The raw and processed datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. All data fully support the findings reported in this article, with no ethical, privacy, or security restrictions limiting data sharing.